Flutamide--an antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency.
Ten men with prostatic cancer, stage T3M0 Nx or more, who were anxious to maintain sexual potency, were treated with flutamide. The eight metastasis-free tumours remained stable during treatment periods of 3-48 months. The two tumours with metastasis at the start of treatment showed growth inhibition for 3 and 7 months, respectively, but thereafter progressed, leading to change of treatment. Nine of the ten men claimed maintained potency during flutamide therapy. Seven delivered ejaculate for biochemical analysis during or after flutamide therapy, as further evidence of potency. Biochemical analyses of the pre-flutamide ejaculates revealed higher values for markers of prostatic secretion in cases with high level of tumour differentiation. Significant reduction in the secreted amount of prostatic and seminal vesicle parameters was found in all the studied cases during flutamide therapy.
Stegmayr
B
B
Department of Internal Medicine, University Hospital, Umeå, Sweden.
Johansson
J E
JE
Schnürer
L B
LB
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000813:Anilides / Q000627:therapeutic use*; D005298:Fertility / Q000187:drug effects*; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000187:drug effects / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012661:Semen / Q000032:analysis
D000813:Anilides; D005485:Flutamide